Huntington National Bank Has $277.32 Million Stock Holdings in Eli Lilly and Company $LLY

Huntington National Bank trimmed its position in Eli Lilly and Company (NYSE:LLY) by 1.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 258,047 shares of the company’s stock after selling 4,009 shares during the period. Eli Lilly and Company makes up approximately 1.7% of Huntington National Bank’s investment portfolio, making the stock its 11th biggest holding. Huntington National Bank’s holdings in Eli Lilly and Company were worth $277,317,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. IPG Investment Advisors LLC raised its position in shares of Eli Lilly and Company by 232.5% in the 4th quarter. IPG Investment Advisors LLC now owns 1,586 shares of the company’s stock valued at $1,704,000 after acquiring an additional 1,109 shares during the period. Connecticut Capital Management Group LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $1,111,000. Smith Chas P & Associates PA Cpas raised its holdings in Eli Lilly and Company by 133.5% during the 4th quarter. Smith Chas P & Associates PA Cpas now owns 1,214 shares of the company’s stock worth $1,305,000 after buying an additional 694 shares during the period. Barry Investment Advisors LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth approximately $325,000. Finally, Severin Investments LLC raised its holdings in Eli Lilly and Company by 3.2% during the 4th quarter. Severin Investments LLC now owns 702 shares of the company’s stock worth $755,000 after buying an additional 22 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company in a combined deal worth up to $3.83 billion, expanding its vaccine and infectious-disease pipeline. Lilly announces three acquisitions to build infectious disease portfolio
• Positive Sentiment: The acquisition spree is being viewed as a strategic move to diversify Lilly’s business and leverage the cash flow generated by its obesity franchise into adjacent high-value markets. Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
• Positive Sentiment: LLY has also been hitting record highs and became the first pharmaceutical company valued at $1 trillion, reinforcing the market’s confidence in its growth story. Eli Lilly Stock Hits Record Highs, Becomes First Pharmaceutical Firm Worth $1 Trillion
• Neutral Sentiment: Additional coverage highlighted continued investor attention around Lilly’s momentum, analyst optimism, and its participation in a Goldman Sachs healthcare conference, but these items are less likely to move the stock on their own. Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
• Neutral Sentiment: Articles comparing Lilly with Novo Nordisk and discussing Trump’s stock purchases do not appear to change the core investment thesis, with Lilly’s fundamentals still seen as the main driver. President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?
• Neutral Sentiment: Competition concerns around Novo Nordisk in the obesity-pill market were framed as manageable rather than a major threat. Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?

Eli Lilly and Company Trading Up 1.9%

LLY stock opened at $1,085.36 on Thursday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company has a fifty day moving average price of $948.23 and a two-hundred day moving average price of $1,007.67. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The stock has a market cap of $1.02 trillion, a price-to-earnings ratio of 38.56, a price-to-earnings-growth ratio of 1.16 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the previous year, the business posted $3.34 earnings per share. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 35.82 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s payout ratio is presently 24.58%.

Analyst Upgrades and Downgrades

Several analysts have commented on LLY shares. HSBC downgraded shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their target price for the stock from $1,070.00 to $850.00 in a report on Tuesday, March 17th. The Goldman Sachs Group restated a “buy” rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a report on Friday, May 22nd. Argus raised their target price on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Morgan Stanley restated an “overweight” rating and set a $1,344.00 target price on shares of Eli Lilly and Company in a report on Friday, May 1st. Finally, Guggenheim restated a “buy” rating and set a $1,183.00 target price on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,227.00.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.